Seres Therapeutics (MCRB) Reports Q3 EPS of $0.72

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to Seres Therapeutics (MCRB) Reports Q3 EPS of $0.72

Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

November 10, 2021 7:00 AM EST

Enrollment completed in SER-109 recurrent C. difficile infection open-label study  

Company expects both completed SER-109 Phase 3 study results and pending safety database to support finalization of Biologics License Application (BLA) filing in mid-2022

Collaboration with Bacthera A.G., a global leader in biopharmaceutical product manufacturing, expands existing capabilities for commercial product supply

SER-109 expanded access program initiated for adults with recurrent C. difficile infection  

Conference call at 8:30 a.m. ET today

CAMBRIDGE, Mass.--(BUSINESS... More